Tumor vaccines with dsRNA adjuvant ARNAX induces antigen-specific tumor shrinkage without cytokinemia

Defined TLR3-specific adjuvant that induces NK and CTL activation without significant cytokine production in vivo

(2015) Misako Matsumoto et al.   Nature Communications

Trial Watch

(2014) Fernando Aranda et al.   OncoImmunology

Targeting TLR3 with no RIG-I/MDA5 activation is effective in immunotherapy for cancer

(2013) Tsukasa Seya et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

TLR3/TICAM-1 signaling in tumor cell RIP3-dependent necroptosis

(2012) Tsukasa Seya et al.   OncoImmunology

Trial Watch

(2012) Lorenzo Galluzzi et al.   OncoImmunology

Cross-priming for antitumor CTL induced by soluble Ag + polyI:C depends on the TICAM-1 pathway in mouse CD11c+/CD8α+dendritic cells

(2012) Masahiro Azuma et al.   OncoImmunology